| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 699 |
| 1 | SOTORASIB | 520 |
| 2 | NIVOLUMAB | 441 |
| 3 | PEMETREXED DISODIUM | 428 |
| 4 | BRIGATINIB | 396 |
| 5 | PACLITAXEL | 394 |
| 6 | PEMETREXED | 357 |
| 7 | IPILIMUMAB | 326 |
| 8 | PACLITAXEL (AIBUMIN-BOUND) | 310 |
| 9 | CRIZOTINIB | 287 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SOTORASIB | 520 | 0.1499 |
| 1 | BRIGATINIB | 396 | 0.1083 |
| 2 | CERITINIB | 130 | 0.0545 |
| 3 | CAPMATINIB | 95 | 0.0402 |
| 4 | AMIVANTAMAB-VMJW | 118 | 0.0330 |
| 5 | CRIZOTINIB | 287 | 0.0225 |
| 6 | PEMETREXED DISODIUM | 428 | 0.0109 |
| 7 | ERLOTINIB HYDROCHLORIDE | 135 | 0.0108 |
| 8 | AFATINIB | 66 | 0.0100 |
| 9 | IPILIMUMAB | 326 | 0.0074 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 1212 |
| 1 | Platinum-based Drug [EPC] | 816 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 667 |
| 3 | Microtubule Inhibitor [EPC] | 512 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 489 |
| 5 | Corticosteroid [EPC] | 399 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 345 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 327 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 205 |
| 9 | Proton Pump Inhibitor [EPC] | 183 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 345 | 0.0072 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 667 | 0.0068 |
| 2 | Microtubule Inhibitor [EPC] | 512 | 0.0031 |
| 3 | Platinum-based Drug [EPC] | 816 | 0.0030 |
| 4 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 17 | 0.0027 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 53 | 0.0025 |
| 6 | Provitamin D2 Compound [EPC] | 68 | 0.0023 |
| 7 | Kinase Inhibitor [EPC] | 1212 | 0.0022 |
| 8 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 18 | 0.0021 |
| 9 | Cannabinoid [EPC] | 12 | 0.0015 |